key: cord-0024526-yz244h21 authors: Lin, Shanshan; Shi, Qingyang; Ge, Zhao; Liu, Yangxi; Cao, Yawen; Yang, Ying; Zhao, Zhiqiang; Bi, Yingfei; Hou, Yazhu; Wang, Shuai; Wang, Xianliang; Mao, Jingyuan title: Efficacy and Safety of Traditional Chinese Medicine Injections for Heart Failure With Reduced Ejection Fraction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials date: 2021-11-30 journal: Front Pharmacol DOI: 10.3389/fphar.2021.659707 sha: a3494a81320209fc95248591dc82cfbb6c48af2d doc_id: 24526 cord_uid: yz244h21 Background: Heart failure as an important issue in global public health, has brought a heavy economic burden. Traditional Chinese medicine injections (TCMIs) have significant effects on heart failure with reduced ejection fraction (HFrEF). However, it is difficult for clinicians to identify the differences in clinical efficacy and safety of various TCMIs. The purpose of this study is to compare the efficacy and safety of various TCMIs for treating HFrEF by conducting a Bayesian network meta-analysis (NMA) and to further provide references for clinical decision-making. Methods: The clinical randomized controlled trials of TCMIs for treating HFrEF were searched in seven database from inception to August 3rd, 2021. The Cochrane collaboration’s tool was used to assess the risk of bias. NMA was performed in a Bayesian hierarchical framework. The surface under the cumulative ranking curve (SUCRA), the multi-dimensional efficacy analysis, the comparison-adjusted funnel plot, and the node-splitting analysis were conducted using R software. Results: A total of 107 eligible RCTs involving 9,073 HFrEF patients and 6 TCMIs were included. TCMIs include Huangqi injection (HQ) also called Astragalus injection, Shenfu injection (SF), Shengmai injection (SGM), Shenmai injection (SM), Xinmailong injection (XML), and Yiqifumai lyophilized injection (YQFM). The results of NMA and SUCRA showed that with conventional treatment (CT) as a common control, in terms of clinical efficacy, CT + XML was most effective in New York Heart Association cardiac functional classification efficiency, brain natriuretic peptide, and N-terminal pro-brain natriuretic peptide; the CT + SM was most effective in 6-min walking test, left ventricular end-diastolic diameter, left ventricular end-systolic diameter and cardiac output; the CT + YQFM was most effective in left ventricular ejection fraction; the CT + HQ was most effective in stroke volume; the CT + SF was most effective in Minnesota Living with Heart Failure Questionnaire. In terms of safety, there was no significant difference between CT + TCMIs and CT. Conclusion: This Bayesian network meta-analysis results show that the combination of qualified TCMIs and CT is more effective for HFrEF patients than CT alone, and CT + XML and CT + SM may be one of the potential optimal treatments. Also, the safety of these TCMIs needs to be further observed. However, due to some limitations, the conclusions need to be verified by more large-sample, double-blind, multi-center RCTs. Heart failure (HF) is defined as a clinical syndrome, characterized by dyspnea, fatigue, fluid retention, etc., caused by a reduced cardiac output and/or elevated intracardiac pressures due to a structural and/or functional cardiac abnormality . It generally occurs in the terminal stage of various cardiovascular diseases, with high morbidity and mortality (Virani et al., 2020) . A China Heart Failure Registry Study (China-HF) conducted between 2012 and 2014 indicated that the in-hospital mortality of HF patients was 5.3% . As standard treatment strategies for HF are constantly being updated and improved, the morbidity and mortality of HF have decreased slightly (Merlo et al., 2014) . However, with the intensified aging of the social demographic structure, the total proportion of HF is expected to rise from 2.42% in 2012 to 2.97% in 2030. The overall cost of HF is continuing to rise, which will increase the global medical and health burden (Heidenreich et al., 2013; Cook et al., 2014; Dokainish et al., 2015; Virani et al., 2020) . Therefore, how to further improve the quality of life and long-term prognosis of HF patients based on modern medicine has attracted increasing attention. Traditional Chinese medicine (TCM) is an empirical medicine with a history of more than 2,000 years and has considerable research value. Especially in the prevention and treatment of coronavirus disease in 2019 , TCM has played an irreplaceable role. Therefore, the clinical value of TCM is worthy of continuous exploration, and it needs more attention from all over the world. Compared with TCM decoctions, which are generally recognized as the most traditional medicine dosage form, the effective ingredients of traditional Chinese medicine injections (TCMIs) can be directly injected into the blood through intravenous injection. On the one hand, it takes effect faster, and on the other hand, it reduces the possibility of the drug being metabolized by the digestive system, thereby ensuring sufficient active ingredients to work. Besides, as modern preparations of TCM extracts, TCMIs have a more standard quality evaluation system than TCM decoctions, so it is easier to obtain high-quality clinical evidence. At present, it has been proved that a large number of TCMIs can significantly improve the clinical efficacy of heart failure with reduced ejection fraction (HFrEF) based on conventional treatment (CT) (Xu T. et al., 2018; Zhu et al., 2018; Lin W. J. et al., 2019; Xie and Dai, 2019; Lin et al., 2021) . However, due to the lack of direct comparative evidence, it is difficult for clinicians to identify the differences in clinical efficacy and safety of various TCMIs and prescribe optimal drugs. Network meta-analysis (NMA) can compare multiple interventions simultaneously in a single analysis by synthesizing direct and indirect evidence, and ranking them according to efficacy or safety (Rouse et al., 2017) . Therefore, this NMA compared the efficacy and safety of various TCMIs in the treatment of HFrEF performed in a Bayesian hierarchical framework (Jansen et al., 2008; Jonas et al., 2013) , and explored the advantages of various TCMIs to provide references for clinical decision-making. ① Conventional treatment for HF (CT HF ) + TCMI vs. CT HF (with or without placebo); ② CT HF + TCMI a vs. CT HF + TCMI b . In the control group and the test group, the CT HF is the same, and both follow national or international guidelines. TCMIs have been approved by the China Food and Drug Administration, and the drug instructions specifically defined its indications including HF or other acute and chronic diseases caused by cardiac insufficiency. • Primary outcomes: ① New York Heart Association (NYHA) cardiac functional classification efficiency: according to the NYHA cardiac function classification standard, the degree of improvement of cardiac function was rated as "markedly effective" (NYHA grade increased by ≥2), "effective" (NYHA grade increased by 1), or "ineffective" (NYHA grade remained unchanged or even deteriorated). Total effective rate ("markedly effective" patients + "effective" patients)/all patients × 100%. ② 6-min walking test (6MWT). • Secondary outcomes: ① left ventricular ejection fraction (LVEF); ② left ventricular end-diastolic diameter (LVEDD); ③ left ventricular end-systolic diameter (LVESD); ④ cardiac output (CO); ⑤ stroke volume (SV); ⑥ brain natriuretic peptide (BNP); ⑦ N-terminal pro-brain natriuretic peptide (NT-proBNP); ⑧ Minnesota Living with Heart Failure Questionnaire (MLHFQ); ⑨ adverse drug event: any untoward medical occurrence during treatment. Clinical randomized controlled trials (RCTs). • Participants were any of the following: HF with malignant arrhythmias, malignant tumors, hypothyroidism, severe liver and kidney dysfunction, or severe infections. • Study with imbalanced or incomparable baseline data between the two groups. • The study cannot be integrated because of incorrect data or incomplete information. • For republished studies, choose the one with the most complete data. • The full text cannot be obtained after seeking help online or contacting the corresponding author via email. • Unfinished protocol. The clinical RCTs of TCMIs for treating HFrEF were searched in the relevant database, including PubMed, Embase, Cochrane Library, Chinese BioMedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Wanfang Database, and VIP Chinese Science and Technology Journal Database (VIP). The retrieval time was from inception to August 3rd, 2021. According to the instructions, TCMIs that meet the inclusion criteria included Huangqi injection (HQ) also called Astragalus injection, Shenfu injection (SF), Shengmai injection (SGM), Shenmai injection (SM), Xinmailong injection (XML), and Yiqifumai lyophilized injection (YQFM). The search strategy was developed according to the Cochrane Handbook for Systematic Reviews (Higgins and Thomas, 2020) by two researchers (SSL with clinical work experience and QYS with evidence-based work experience). Search terms included heart failure, names of TCMIs that have been included, randomized controlled trial, and their synonyms. Besides, the reference lists of related documents were tracked to avoid omission. Take PubMed as an example. The detailed search strategy is shown in Supplementary File S2. Records from databases were managed and screened using NoteExpress software (V3.2.0). The data extraction items included publication information (title, first author, journal name, publication year), participants' characteristics (diagnostic criteria, sample size, sex, age, ethnicity, case source, and baseline status), interventions (drug name, medication route, drug dose, course of treatment, and patient compliance), outcomes, risk of bias information, and others. The Cochrane Collaboration's tool (Higgins et al., 2011) was used to assess the risk of bias of included RCTs from the following seven items: ① random sequence generation; ② allocation concealment; ③ blinding participants and personnel; ④ blinding outcome assessment; ⑤ incomplete outcome data; ⑥ selective reporting; and ⑦ other bias. The results of the risk of bias assessment included the low risk of bias, the high risk of bias, and the unclear risk of bias. Data extraction and risk of bias assessment were independently completed and cross-checked by multiple researchers. Disagreements were resolved with the assistance of other researchers. The risk of bias graph was generated by Microsoft Excel. A Bayesian model was used to conduct NMAs according to the Markov chain Monte Carlo method (Jansen et al., 2008) . Dichotomous variables were presented as the relative risk (RR) or odds ratio (OR) with a 95% credible interval (CrI). Continuous variables were presented as the weight mean difference (WMD) with a 95% CrI. The χ 2 test and Ι 2 test were conducted to assess the potential heterogeneity. p < 0.05 was considered statistically significant. The random-effects model was selected to synthesize the data. The network diagram of each outcome was performed to visualize the connections between different interventions. The surface under the cumulative ranking curve (SUCRA) was performed to rank different interventions (Rücker and Schwarzer, 2015) . The multi-dimensional efficacy analysis was performed to integrate the results of multiple outcomes to obtain the optimal intervention. The comparison-adjusted funnel plot was plotted to detect small sample size study effects and publication bias. The node-splitting analysis was used to split mixed evidence into direct evidence and indirect evidence to evaluate the consistency of the model. All analyses were conducted using R software (V3.6.1). A total of 9,360 records were initially obtained, and 2,344 possible related records were identified by reading the title and abstract. After reading the full text, 107 eligible studies were included in this NMA. The details of the literature screening process are shown in Figure 1 . Age is described in the form of mean ± standard deviation or mean (minimum ∼ maximum). # "CT HF " refers to the conventional treatment for heart failure in the international heart failure guidelines, including angiotensin-converting enzyme inhibitor (such as captopril, enalapril), angiotensin receptor blocker (such as valsartan, irbesartan), β-blocker (such as metoprolol), mineralocorticoid receptor antagonists (spironolactone), cardiotonic drugs (such as digoxin), anticoagulant and antiplatelet drugs(such as aspirin), and so on. These drugs were the conventional doses recommended in the guidelines and needed to be adjusted according to the patient's condition, especially β-blockers and diuretics. However, the treatment plan and principles of the "CT HF " of the test group and the control group were the same. LVEF, left ventricular ejection fraction; F, female; M, male; T, test group; C, control group; HQ, Huangqi injection; SF, Shenfu injection; SGM, Shengmai injection; SM, Shenmai injection; XML, Xinmailong injection; YQFM, Yiqifumai lyophilized injection; d, day(s); w, week(s). ① New York Heart Association cardiac functional classification efficiency; ② 6-min walking test; ③ left ventricular ejection fraction; ④ left ventricular end-diastolic diameter; ⑤ left ventricular end-systolic diameter; ⑥ cardiac output; ⑦ stroke volume; ⑧ brain natriuretic peptide; ⑨ N-terminal pro-brain natriuretic peptide; ⑩ Minnesota Living with Heart Failure Questionnaire; ⑪ adverse drug event. Frontiers in Pharmacology | www.frontiersin.org November 2021 | Volume 12 | Article 659707 Frontiers in Pharmacology | www.frontiersin.org November 2021 | Volume 12 | Article 659707 10 β-blocker, mineralocorticoid receptor antagonists, diuretics, vasodilators, cardiotonic drugs, antiplatelet drugs, anticoagulant drugs, and so on. There was slight variability in the medication depending on the patient's condition. However, the medication principles of all RCTs followed the recommendations of the guidelines. The course of treatment ranged from 5 days to 12 weeks. Details are shown in Table 1 . The network diagrams of the above 6 TCMIs with different outcomes are shown in Figure 2 . The results of the risk of bias assessment are as follows. ① Random sequence generation: 34 studies (Wang, 2003; Hu, et al., 2009; Zhang et al., 2014; Yao et al., 2016; Zhang et al., 2018; Qi and Qi, 2015; Song et al., 2006; Xu et al., 2014; Wang et al., 2011; Pan, 2015; Yan et al., 2017; Li X. L., 2018; Pan, 2013; Kong, 2010; Zhai, 2013; An and Xiao, 2019; He et al., 2020; He et al., 2018; Xu S. L. et al., 2018; Wang, 2017; Xue et al., 2019; Xu E. W. et al., 2018; Li J. F., 2018; Zhang, 2018; Tao et al., 2020; Wang et al., 2021; Jiang 2021; Kou 2021) were evaluated as low risk due to the use of a random number table, one study that was randomly grouped according to the order of visits was assessed as high risk, and other studies did not describe specific randomization methods. ② Allocation concealment: one study was evaluated as low risk due to the use of center allocation, and one study was evaluated as high risk due to the failure of allocation concealment. ③ Blinding participants and personnel: two double-blind studies (Qi, 2015; Xue et al., 2019) were evaluated as low risk, two singleblind study (Wu and Duan, 2009; was high-risk, and other studies did not mention blinding. ④ Blinding outcome assessment: one study using center allocation was evaluated as low-risk, and other studies did not mention whether the evaluators were blinded. ⑤ Incomplete outcome data: there was no missing data in all studies. ⑥ Selective report: all studies did not provide a protocol, so the risk of selective reporting was unclear. ⑦ Other bias: there was not enough information to assess whether there were other biases. The summary of the risk of bias of the included RCTs is shown in Figure 3 . A total of 48 RCTs reported the NYHA cardiac functional classification efficiency, including six types of TCMIs and seven types of interventions (CT vs. CT + HQ (n 4), CT vs. CT + SF (n 28), CT vs. CT + SGM (n 3), CT vs. CT + SM (n 4), CT vs. CT + XML (n 6), CT vs. CT + YQFM (n 2), and CT + SM vs. CT + XML (n 1)) ( Table 1 ). The network diagram is shown in Figure 2 . All TCMIs combined with CT were superior to CT alone, and the difference was statistically significant. The details are shown in According to SUCRA probability results ( Figure 4 ; Table 3 ), CT + XML was the most likely to be the best intervention for improving the NYHA cardiac functional classification efficiency. The ranking of seven interventions is as follows: CT + XML (81.36%) > CT + HQ (80.87%) > CT + SM (62.19%) > CT + SF (58.46%) > CT + SGM (34.68%) > CT + YQFM (32.39%) > CT (0.05%). A total of 31 RCTs reported 6MWT, including five types of TCMIs and six types of interventions (CT vs. CT + SF (n 7), CT vs. CT + SM (n 7), CT vs. CT + XML (n 13), CT vs. CT + YQFM (n 3), and CT + SM vs. CT + XML (n 1)) ( Table 1 ). The network diagram is shown in Figure 2 . Apart from HQ, other TCMIs combined with CT were superior to CT alone, and the difference was statistically significant. The details are shown in FIGURE 3 | Risk of bias graph of the included RCTs. The vertical axis represents the risk of bias items, and the horizontal axis represents the percentage of the number of RCTs. For the outcome whose evaluation process is objective, the "unclear risk of bias" should be regarded as "low risk of bias". Frontiers in Pharmacology | www.frontiersin.org November 2021 | Volume 12 | Article 659707 According to SUCRA probability results ( Figure 4 ; Table 3 ), CT + SM was the most likely to become the best intervention for improving 6MWT. The ranking of six interventions is as follows: CT + SM (82.25%) > CT + XML (77.40%) > CT + YQFM (61.84%) > CT + SF (57.62%) > CT (16.60%) > CT + HQ (4.30%). A total of 91 RCTs reported LVEF, including six types of TCMIs and seven types of interventions (CT vs. CT + HQ (n 7), CT vs. CT + SF (n 28), CT vs. CT + SGM (n 7), CT vs. CT + SM (n 19), CT vs. CT + XML (n 20), CT vs. CT + YQFM (n 7), CT + HQ vs. CT + XML (n 1), CT + SM vs. CT + XML (n 1), and CT + SGM vs. CT + SF (n 1)) ( Table 1 ). The network diagram is shown in Figure 2 . All TCMIs combined with CT were superior to CT alone, and the difference was statistically significant. The details are shown in Table 2 . The bolded values indicate statistical significance. NYHA, New York Heart Association cardiac functional classification efficiency; 6WMT, 6-min walking test; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; CO, cardiac output; SV, stroke volume; BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide; MLHFQ, Minnesota Living with Heart Failure Questionnaire; CT, conventional treatment; HQ, Huangqi injection; SF, Shenfu injection; SGM, Shengmai injection; SM, Shenmai injection; XML, Xinmailong injection; YQFM, Yiqifumai lyophilized injection. a Indicates that the value is odds ratio. According to SUCRA probability results (Figure 4 ; Table 3 ), CT + YQFM was the most likely to become the best intervention for improving LVEF. The ranking of seven interventions is as follows: CT + YQFM (85.88%) > CT + SM (74.75%) > CT + SF (52.46%) > CT + HQ (51.52%) > CT + XML (48.54%) > CT + SGM (36.85%) > CT (0.01%). A total of 38 RCTs reported LVEDD, including six types of TCMIs and seven types of interventions (CT vs. CT + HQ (n 2), CT vs. CT + SF (n 15), CT vs. CT + SGM (n 2), CT vs. CT + SM (n 8), CT vs. CT + XML (n 8), and CT vs. CT + YQFM (n 3)) ( Table 1 ). The network diagram is shown in Figure 2 . Apart from HQ and YQFM, other TCMIs combined with CT were superior to CT alone, and the difference was statistically significant. In addition, there were also statistically significant differences between different injections, such as CT + SF vs. CT + SGM, CT + SF vs. CT + SM, CT + SF vs. CT + XML, CT + SF vs. CT + YQFM, and CT + XML vs. CT + YQFM. The details are shown in Table 2 . According to SUCRA probability results (Figure 4 ; Table 3 ), CT + SM was the most likely to become the best intervention for improving LVEDD. The ranking of seven interventions is as follows: CT + SM (82.06%) > CT + XML (75.00%) > CT + SGM (74.36%) > CT + SF (47.04%) > CT + HQ (34.69%) > CT + YQFM (31.51%) > CT (5.34%). A total of 15 RCTs reported LVESD, including six types of TCMIs and seven types of interventions (CT vs. CT + HQ (n 2), CT vs. CT + SF (n 3), CT vs. CT + SGM (n 2), CT vs. CT + SM (n 4), CT vs. CT + XML (n 3), and CT vs. CT + YQFM (n 1)) ( Table 1 ). The network diagram is shown in Figure 2 . Table 2 shows that only XML combined with CT were superior to CT alone, and the difference was statistically significant. According to SUCRA probability results ( Figure 4 ; Table 3 ), CT + SM was the most likely to become the best intervention for improving LVESD. The ranking of six interventions is as follows: CT + SM (84.72%) > CT + YQFM (72.23%) > CT + SGM (49.29%) > CT + HQ (47.73%) > CT + SF (46.65%) > CT + XML (44.75%) > CT (4.63%). A total of 19 RCTs reported CO, including five types of TCMIs and six types of interventions (CT vs. CT + HQ (n 2), CT vs. CT + SF (n 7), CT vs. CT + SGM (n 5), CT vs. CT + SM (n 3), CT vs. CT + XML (n 1), and CT + SF vs. CT + SGM (n 1)) ( Table 1 ). The network diagram is shown in Figure 2 . Apart from XML, other TCMIs combined with CT were superior to CT alone, and the difference was statistically significant. The details are shown in Table 2 . According to SUCRA probability results (Figure 4 ; Table 3 ), CT + SM was the most likely to become the best intervention for improving CO. The ranking of six interventions is as follows: CT + SM (75.03%) > CT + HQ (73.69%) > CT + SGM (66.25%) > CT + SF (51.43%) > CT + XML (28.52%) > CT (5.08%). A total of 24 RCTs reported SV, including five types of TCMIs and six types of interventions (CT vs. CT + HQ (n 3), CT vs. CT + SF (n 7), CT vs. CT + SGM (n 4), CT vs. CT + SM (n 6), CT FIGURE 4 | Surface under the cumulative ranking curve (SUCRA) plots for different outcomes. The vertical axis represents cumulative probabilities and the horizontal axis represents rank. NYHA, New York Heart Association cardiac functional classification efficiency; 6WMT, 6-min walking test; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; CO, cardiac output; SV, stroke volume; BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide; MLHFQ, Minnesota Living with Heart Failure Questionnaire; CT, conventional treatment; HQ, Huangqi injection; SF, Shenfu injection; SGM, Shengmai injection; SM, Shenmai injection; XML, Xinmailong injection; YQFM, Yiqifumai lyophilized injection. vs. CT + XML (n 3), and CT + SF vs. CT + SGM (n 1)) ( Table 1 ). The network diagram is shown in Figure 2 . Table 2 shows that only HQ, SF, and YQFM combined with CT were superior to CT alone, and the difference was statistically significant. According to SUCRA probability results ( Figure 4 ; Table 3 ), CT + HQ was the most likely to become the best intervention for improving SV. The ranking of six interventions is as follows: CT + HQ (82.24%) > CT + SF (72.55%) > CT + XML (64.18%) > CT + SM (44.51%) > CT + SGM (33.85%) > CT (2.68%). A total of 32 RCTs reported BNP, including five types of TCMIs and six types of interventions (CT vs. CT + HQ (n 2), CT vs. CT + SF (n 14), CT vs. CT + SGM (n 1), CT vs. CT + SM (n 4), CT vs. CT + XML (n 9), CT + HQ vs. CT + XML (n 1), and CT + SM vs. CT + XML (n 1)) ( Table 1 ). The network diagram is shown in Figure 2 . Table 2 shows that only SF and XML combined with CT were superior to CT alone, and the difference was statistically significant. According to SUCRA probability results ( Figure 4 ; Table 3 ), CT + XML (87.11%) was the most likely to become the best intervention for improving BNP. The ranking of six interventions is as follows: CT + XML (87.16%) > CT + SF (69.84%) > CT + SM (61.54%) > CT + HQ (34.67%) > CT + SGM (31.67%) > CT (15.12%). A total of 31 RCTs reported NT-proBNP, including five types of TCMIs and six types of interventions (CT vs. CT + SF (n 11), CT vs. CT + SGM (n 1), CT vs. CT + SM (n 7), CT vs. CT + XML (n 8), and CT vs. CT + YQFM (n 4)) ( Table 1 ). The network diagram is shown in Figure 2 . Table 2 shows that only SF, SM, and XML combined with CT were superior to CT alone, and the difference was statistically significant. According to SUCRA probability results (Figure 4 ; Table 3 ), CT + XML was the most likely to become the best intervention for improving NT-proBNP. The ranking of six interventions is as follows: CT + XML (86.74%) > CT + SM (68.73%) > CT + SGM (51.07%) > CT + SF (45.71%) > CT + YQFM (39.25%) > CT (8.51%). A total of 11 RCTs reported MLHFQ, including five types of TCMIs and six types of interventions (CT vs. CT + HQ (n 1), CT vs. CT + SF (n 3), CT vs. CT + SM (n 2), CT vs. CT + XML (n 4), and CT vs. CT + YQFM (n 1)) ( Table 1 ). The network diagram is shown in Figure 2 . Table 2 shows that only SF and XML combined with CT were superior to CT alone, and the difference was statistically significant. According to SUCRA probability results ( Figure 4 ; Table 3 ), CT + SF was the most likely to become the best intervention for improving MLHFQ. The ranking of six interventions is as follows: CT + SF (72.90%) > CT + XML (70.03%) > CT + HQ (62.91%) > CT + SM (48.88%) > CT + YQFM (35.95%) > CT (9.73%). Forty RCTs focused on adverse drug reactions (ADRs), mainly including dizziness and headache, gastrointestinal discomfort, skin allergic reactions, lowered blood pressure, and abnormal heart rhythm. Considering that the criteria for ADR in each RCT were not completely consistent, a descriptive analysis was carried out. Given the small sample size, it is not yet possible to prove that the difference between the two groups is statistically significant. Details are shown in Tables 1, 4. This multi-dimensional efficacy analysis method integrated the results of multiple outcomes to obtain the optimal intervention. The results based on currently available clinical data indicate that, in terms of the primary outcomes (NYHA cardiac functional classification efficiency and 6WMT), CT + XML and CT + SM may be the best two treatments, followed by CT + SF, CT + YQFM, CT + HQ, and CT + SGM ( Figure 5A ). In terms of NYHA cardiac functional classification efficiency and the most The redder the color, the greater the SUCRA, and the greater the probability of becoming the best intervention. The greener the color, the smaller the SUCRA, and the smaller the probability of becoming the best intervention. NYHA, New York Heart Association cardiac functional classification efficiency; 6WMT, 6-min walking test; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; CO, cardiac output; SV, stroke volume; BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide; MLHFQ, Minnesota Living with Heart failure questionnaire; CT, conventional treatment; HQ, Huangqi injection; SF, Shenfu injection; SGM, Shengmai injection; SM, Shenmai injection; XML, Xinmailong injection; YQFM, Yiqifumai lyophilized injection. Frontiers in Pharmacology | www.frontiersin.org common cardiac ultrasound index LVEF, CT + SM, CT + HQ, CT + XML, and CT + YQFM may all be potentially optimal choices ( Figure 5B) . Also, in terms of NYHA cardiac functional classification efficiency and the most common laboratory test index BNP, CT + XML may be the optimal choice ( Figure 5C ). The comparison-adjusted funnel plots for each outcome were plotted, the result of LVEF with the biggest sample size is shown in Figure 6 . The points in the funnel chart were asymmetric based on the position of the centerline, and the scatter was found to be symmetrical along the null line to the left and right, indicating that there was no small sample effect and publication bias. Funnel plots of all outcomes were shown in Supplementary File S3. As shown in Figure 2 , there are some closed loops in the NYHA cardiac function classification efficiency, 6WMT, LVEF, CO, SV, and BNP network diagram. Therefore, the node-splitting analysis was used to evaluate the inconsistency of the model. Figure 7 shows that there . It is worth mentioning that TCM is not only widely used in China, but also transported to and served in many epidemic areas around the world. The unique advantages and clinical value of TCM have received increasing attention from all over the world. TCM has accumulated thousands of years of clinical experience in the treatment of many diseases. Among them, HF is one of the dominant diseases of TCM. In 2018, the "Guidelines for diagnosis and treatment of heart failure in China 2018" (Heart Failure Group of Chinses Society of Cardiology of Chinses Medical Association et al., 2018) officially listed TCM as a recommendation for the treatment of HF. At present, the combination of traditional Chinese and Western medicine has become the basic model for the treatment of HF in China. Epidemiological investigations show that the common pathogenesis includes hypertension, cardiomyopathy, rheumatic heart disease, etc., of which ischemic heart disease is a major contributor to HF in Asia (Sakata and Shimokawa, 2013) . According to the theory of TCM, the main pathogenesis of HF is "Qi deficiency (the lack of energy in the body in modern medicine, usually manifested as fatigue, spontaneous sweating, etc.) and blood stasis (an abnormal hemodynamic state in which blood tends to clot in modern medicine)". The raw materials for the preparation of TCMIs are derived from total extracts, active parts or monomeric active ingredients extracted from traditional herbal medicines or traditional animal medicines. Through modern technology, further liquid preparation, purification, distillation, sterilization, etc. are accurately implemented to complete the entire preparation process. The TCMIs included in this study all have the effect of nourishing Qi and blood. And a large number of articles and reviews have explored the protective effects of the active ingredients of these TCMIs on cardiovascular diseases in terms of molecular mechanisms, such as Huang-Qi (Radix Astragali) (Su et al., 2021) in HQ, the combination of Ren-Shen (Radix Ginseng) and Fu-Zi (processed) (Radix Aconiti Lateralis Preparata) (Tan et al., 2018; in SF, the combination of Hong-Shen (Radix Ginseng Rubra) and Mai-Dong (Radix Ophiopogonis) in SM and YQFM, Wu-Wei-Zi (Fructus Schisandrae) (Nasser et al., 2020) in SGM, and American cockroach (Periplaneta Americana Linnaeus) (Qi et al., 2017; in XML. Due to the available active ingredients, rich and diverse targets, and complex regulatory mechanisms, TCMIs have considerable development potential. This study clarified the clinical advantages of different TCMIs by performing an NMA. On the one hand, it will provide a reference for the rational use of TCMIs. On the other hand, molecular studies based on the clinical characteristics of TCMIs can provide ideas and clues for the development of new drugs. This NMA incorporated 107 RCTs on the efficacy and safety of TCM combined with CT in the treatment of HFrEF, including 9,073 patients and 6 TCMs. Among them, TCMIs include HQ, SF, SGM, SM, XML, and YQFM. In terms of clinical efficacy, the combination of CT + XML may be the most effective in improving NYHA cardiac functional classification efficiency, BNP, and NT-proBNP; the combination of CT + SM may be the most effective in improving 6MWT, LVEDD, LVESD, and CO; the combination of CT + YQFM may be the most effective in improving LVEF; the combination of CT + HQ may be the most effective in improving SV; the combination of CT + SF may be the most effective in improving MLHFQ. The results based on currently available clinical data show that the ranking results of TCMIs in various outcomes are inconsistent. Each species has its own advantages. Among them, the overall evaluation of CT + XML and CT + SM is relatively good. In terms of safety, CT + TCMIs may cause additional ADR events. However, there was no significant difference compared with the CT. The recommendation of clinical drugs requires a multi-dimensional evaluation system. In this study, NYHA and 6WMT were used as the primary outcome indicators for the comprehensive evaluation, and the results showed that CT + XML and CT + SM may be the best two treatments, followed by CT + SF, CT + YQFM, CT + HQ, and CT + SGM. Depending on the research focus and the primary outcome indicators, the conclusions may change accordingly. In this study, there is no proof of publication bias. In addition, there are both direct comparison and indirect comparison evidence in the evaluation of six outcome indicators, including NYHA cardiac function classification efficiency, 6WMT, LVEF, CO, SV, and BNP. The consistency test results showed that, except for BNP, the consistency between the direct and indirect research evidence of other outcome indicators was good, and the evidence-based conclusions were stable and reliable. The increase in BNP is related to many diseases. In addition to HF, senile diseases such as atrial fibrillation (Silvet et al., 2003) , chronic obstructive pulmonary disease (Inoue et al., 2009) , and renal insufficiency (McCullough et al., 2003) can also cause non-specific increases in BNP. Although this study excluded patients with severe comorbidities as much as possible, the included population was mostly elderly patients, and individual differences had a greater impact on BNP levels, which may be the reason for the unstable evidence of BNP. At present, some researchers have performed NMAs on TCMIs for the treatment of HF Yang et al., 2018) . However, these studies did not consider the clinical heterogeneity between HF patients with different types of ejection fraction. A study showed that compared with heart failure with preserved ejection fraction (HFpEF), HFrEF is more related to high levels of BNP, troponin T, creatinine, uric acid, glycosylated hemoglobin levels, and the proportion of coronary heart disease . Considering that there may be significant differences in the pathophysiological process between HFrEF and HFpEF (Putko et al., 2021) , we believe that research on different types of HF is more realistic for exploring personalized treatment plans. Therefore, we selected HFrEF with more severe clinical symptoms and more sufficient clinical data as the research object to reduce clinical heterogeneity and obtain more reliable evidence. In addition, this study has some limitations: ① The overall quality of the included RCTs is low. Most RCTs did not report in detail on random methods, blinding, allocation concealment, and program registration. These limitations may lead to serious risks of bias. Therefore, it is recommended that clinical research should be implemented strictly in accordance with the CONSORT checklist (Moher et al., 2012) . ② Due to the lack of clinical data, this study failed to report outcomes that directly reflect the clinical benefit and prognosis of patients, such as mortality and rehospitalization rates. ③ Since all the studies were conducted in China, the external adaptability of the conclusions will be limited to a certain extent. In summary, the NMA results show that compared with CT alone, the combination of qualified TCMIs and CT is more effective for HFrEF patients. Among them, CT + XML and CT + SM may be the potential optimal treatment. Besides, the safety of these TCMIs needs to be further observed through more studies using unified observation indicators that reflect safety. However, due to some limitations, the conclusions need to be verified by more large-sample, double-blind, multicenter RCTs in the future. SL is responsible for the entire research design process, especially conceptualization and methodology. JM and XW were responsible for the conceptualization, funding acquisition, and project administration. All the authors took part in the data curation, formal analysis, and visualization. SL finished the writing-original draft and all the authors participated in the writing-review and editing. . The funder has not taken part in the study design, data collection and analysis, the decision to publish, or the preparation of the article. SM (22 RCTs, 20.56%) (Chen and Zhou An and Xiao SGM (10 RCTs, 9.35% HQ (8 RCTs, 7.48%) (Liu and Fu and YQFM Heart Failure Group of Chinses Society of Cardiology of Effects of Shenmai Injection Combined with Irbesartan on Plasma BNP and Cardiac Function in Patients with Chronic Heart Failure Treatment of 30 Cases of Chronic Congestive Heart Failure with Shenfu Injection Clinical Observation of Shenmai Injection in the Treatment of Chronic Congestive Heart Failure Clinical Analysis of Shengmai Injection in the Treatment of 36 Cases of Chronic Heart Failure Evaluation of Shenfu Injection in Patients with Dilated Cardiomyopathy Clinical Analysis of Shenmai Injection Combined with Bisoprolol in the Treatment of Chronic Heart Failure The Annual Global Economic burden of Heart Failure Efficacy of Shenmai Injection Combined with Furosemide in the Treatment of Heart Failure and its Effects on Plasma Hcy, NT-proBNP, and Leptin Comparison of Efficacy of Different Doses of Shenfu Injection in the Treatment of Chronic Heart Failure Effect of Shengmai Injection on Heart Function in Patients with Chronic Heart Failure Combined with Coronary Heart Disease Clinical Observation of Shenfu Injection in the Treatment of Chronic Systolic Heart Failure Heart Failure in Low-and Middle-Income Countries: Background, Rationale, and Design of the International Congestive Heart Failure Study (INTER-CHF) Effect of Shenfu Injection Combined with Western Medicine in the Treatment of Coronary Heart Disease with Heart Failure and its Effect on BNP Effect of Xinmailong Injection on Serum hsCRP, BNP and LDL-C in Patients with Heart Failure of Coronary Heart Disease Efficacy of Astragalus Injection in the Treatment of Chronic Heart Failure and its Effect on BNP and CA125 Treatment of 42 Cases of Chronic Congestive Heart Failure with Huangqi Injection Clinical Observation of Yiqi Fumai Injection in the Treatment of Chronic Heart Failure Analysis of the Effect of Shenfu Injection in the Treatment of Heart Failure of Coronary Heart Disease The Effect of Xinmailong Injection in Patients with Chronic Heart Failure Clinical Study of Xinmailong Injection in the Treatment of Patients with Heart Failure Reduced Ejection Fraction. Master's thesis Clinical Observation of Shenmai Injection Combined with Levosimendan in the Treatment of Severe Heart Failure Therapeutic Effect of Shenmai Injection Combined with Milrinone in Treatment of Refractory Heart Failure Effect of Shenfu Injection on Cardiac Function and Ventricular Remodeling in Patients with Dilated Cardiomyopathy with Heart Failure Heart Failure Group of Chinses Society of Cardiology of Chinses Medical Association; Chinses Heart Failure Association of Chinses Medical Doctor Association; Editorial Board of Forecasting the Impact of Heart Failure in the United States: a Policy Statement from the The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials Influence of Shenfu Injection on Heart Function and Bone Marrow Stem Cell Mobilization in Patients with Chronic Heart Failure of Coronary Heart Disease Influence of Shenmai Injection on Chronic Contractive Heart Failure Patients' Heart Function and BNP Clinical Study of Shenfu Injection in the Treatment of Senile Chronic Heart Failure The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-Analyses of Health Care Interventions: Checklist and Explanations High Plasma Brain Natriuretic Peptide Levels in Stable COPD without Pulmonary Hypertension or Cor Pulmonale 2020). (Version 6.1) Cochrane Handbook for Systematic Reviews of Interventions Bayesian Meta-Analysis of Multiple Treatment Comparisons: an Introduction to Mixed Treatment Comparisons Analysis of the Effect of Shenmai Injection Combined with Furosemide on Patients with Findings of Bayesian Mixed Treatment Comparison Meta-Analyses: Comparison and Exploration Using Real-World Trial Data and Simulation Agency for Healthcare Research and Quality US. Report No.: 13-EHC039-EF Study on Shengmai Injection in Patients with Chronic Heart Failure of Type Qi and Yin Deficiency Clinical Effect Analysis of Digoxin Tablets Combined with Yiqi Fumai in the Treatment of Chronic Heart Failure Clinical Observation of Shenmai Injection in the Treatment of Chronic Congestive Heart Failure Effect of Shen Mai Injection on Left Ventricular Pump Function in 60 Patients with Coronary Heart Disease and Heart Failure Effect of Xinmailong Injection on Serum Cystatin C and Cardiac Function in Elderly Patients with Chronic Heart Failure Effects of Shenfu Injection Combined with Creatine Phosphate Sodium on Cardiac Function, Heart Rate Variability, and Serum BNP in Patients with Dilated Cardiomyopathy and Heart Failure Clinical Effect of Shenmai Injection Combined with Trimetazidine in the Treatment of Dilated Cardiomyopathy Complicated with Heart Failure. Chin Shenmai Injection Protects against Doxorubicin-Induced Cardiotoxicity via Maintaining Mitochondrial Homeostasis Clinical Observation of Trimetazidine Combined with Shenfu Injection in the Treatment of Chronic Heart Failure Clinical Observation on Treating Chronic Heart Failure and Hypotension with the Shengmai Injection Plus Conventional Western Medicine Effect of Shenmai Injection on Therapeutic Effect and N-Terminal Brain Natriuretic Peptide in Patients with Heart Failure Clinical Observation of Yiqi Fumai Injection (Freeze-dried) in the Treatment of Dilated Cardiomyopathy Clinical Observation on Xinmailong Injection Combined with Nicorandil in Treatment of Elderly Chronic Heart Failure with Reduced Ejection Fraction Clinical Efficacy of Shenmai Injection in the Treatment of Senile Heart Failure and its Effect on Traditional Chinese Medicine Injections for Heart Failure: a Protocol for Systematic Review and Network Meta-Analysis of Randomised Controlled Trials Xinmailong Injection in the Treatment of Heart Failure with Different Types of Ejection Fraction: a Systematic Review Intervention Mechanisms of Xinmailong Injection, a periplaneta Americana Extract, on Cardiovascular Disease: a Systematic Review of Basic Researches The Hemodynamic Effects of Huangqi Injection in the Treatment of Chronic Heart Failure: a Meta-Analysis of Treatment of Congestive Heart Failure with Huangqi Injection Effect of Xinmailong Injection on Brain Natriuretic Peptide Precursor and High Sensitivity C-Reactive Protein in Patients with Dilated Cardiomyopathy Study in Clinical Data from Heart Failure Patients with Preserved and Reduced Ejection Fraction. Chin Effect of Shenfu Injection on CD4+ CD25+ CD127low/-Regulatory T Cells in Peripheral Blood of Patients with Chronic Heart Failure Clinical Observation of Shengmai Injection in the Treatment of 120 Cases of Chronic Heart Failure Clinical Research on the Treatment of Heart Failure Caused by the Dilated Cardiomyopathy with Xinmailong Injection. Master's thesis Clinical Observation of Shengmai Injection in the Treatment of Chronic Heart Failure Analysis of Therapeutic Effect of Shenfu Injection on 31 Cases of Dilated Cardiomyopathy Clinical Effect of Shenfu Injection on Patients with Chronic Heart Failure of Coronary Heart Disease Clinical Observation of Xinmailong Injection in the Treatment of Dilated Cardiomyopathy with Heart Failure B-Type Natriuretic Peptide and Renal Function in the Diagnosis of Heart Failure: an Analysis from the Breathing Not Properly Multinational Study CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure with Reduced Ejection Fraction Long-term Prognostic Impact of Therapeutic Strategies in Patients with Idiopathic Dilated Cardiomyopathy: Changing Mortality over the Last 30 Years CONSORT 2010 Explanation and Elaboration: Updated Guidelines for Reporting Parallel Group Randomised Trials Clinical Study of Pulse-Activating Injection Combined with Phentolamine on Treating Chronic Heart Failure Clinical Observation of Shenfu Injection in the Treatment of Senile Chronic Heart Failure. Chin Effect of Xinmailong Injection on Elderly Patients with Chronic Heart Failure 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Mid-regional Pro-atrial Natriuretic Peptide, and Prognosis across a Range of Ejection Fractions in Heart Failure Clinical Observation of Shenfu Injection in the Treatment of Dilated Cardiomyopathy with Intractable Heart Failure Mechanisms of Chinese Medicine Xinmailong's protection against Heart Failure in Pressure-Overloaded Mice and Cultured Cardiomyocytes Comparison of the Therapeutic Effect of Shenfu Injection and Shengmai Injection in the Treatment of Chronic Heart Failure SHENFU Injection on Treatment of 32 Cases of Ectatic Cardiomyopathy Network Meta-Analysis: an Introduction for Clinicians Ranking Treatments in Frequentist Network Meta-Analysis Works without Resampling Methods Epidemiology of Heart Failure in Asia Brain Natriuretic Peptide Is Elevated in Outpatients with Atrial Fibrillation Clinical Observation of Shenfu Injection in the Treatment of Chronic Systolic Heart Failure Clinical Observation of Xinmailong Injection in the Treatment of Chronic Heart Failure Effect of Xinmailong Injection on Treating of Refractory Heart Failure Phytochemistry and Cardiovascular Protective Effects of Huang-Qi (Astragali Radix) Clinical Analysis of Creatine Phosphate Sodium Combined with Shenfu Injection in the Treatment of Dilated Cardiomyopathy with Cardiac Insufficiency Clinical Study of Huangqi Injection in the Treatment of Chronic Heart Failure Cross-platform Metabolic Profiling Deciphering the Potential Targets of Shenfu Injection against Acute Viral Myocarditis in Mice Effect of Xinmailong on QT Dispersion and Clinical Efficacy in Patients with Ischemic Heart Failure Clinical Study on Yiqi Fumai Lyophilized Injection in Treatment of Chronic Heart Failure with Hypotension Heart Disease and Stroke Statistics-2020 Update: a Report from the Effect of Shenfu Injection on Serum CA125 and Troponin I in Patients with Chronic Congestive Heart Failure. Chin Effect of Shenmai Injection for Treatment of Dilated Cardiomyopathy Congestive Heart Failure Effect of Shenfu Injection in the Treatment of Dilated Cardiomyopathy with Heart Failure Clinical Effects of Shenfu Injection in the Treatment of Patients with Dilated Cardiomyopathy Combined with Chronic Systolic Heart Failure The Impact of Shenfu Injection on the Immune Function in Patients with Chronic Heart Failure and Heart-Kidney Yang Deficiency Syndrome Comparative Efficacy of Chinese Herbal Injections for Treating Chronic Heart Failure: a Network Meta-Analysis Protective Mechanism of Shenmai on Myocardial Ischemia-Reperfusion through the Energy Metabolism Pathway Analysis of Efficacy of Metoprolol Combined with Xinmailong Injection in the Treatment of Patients with Chronic Heart Failure Frontiers in Pharmacology | www.frontiersin.org Combined Metoprolol and Huangqi Injection to Treating 35 Cases of Heart Failure from Ischemic Heart Disease Ginseng Injection in the Treatment of Dilated Cardiomyopathy Heart Failure Qi and Yin Deficiency Syndrome in Clinical Research. Master's thesis Clinical Research of Curative Effect and Short-Term Prognosis of Xinmailong Injection in the Treatment of Patients with Chronic Heart Failure. Master's thesis Analysis of Efficacy and Safety of Xinmailong Injection in the Treatment of Chronic Heart Failure Clinical Observation of Huangqi Injection in the Treatment of 26 Cases of Dilated Cardiomyopathy with Heart Failure Clinical Study of Shenfu Injection for Heart Failure of Coronary Heart Disease Clinical Observation of Shenfu Injection in Treating Congestive Heart Failure in Elderly Patients Influence of Shenfu Injection on Cardiac Function and Content of NT-proBNP in Patients with Chronic Heart Failure Observation of Curative Effect of Xinmailong Combined with Dobutamine on Chronic Cardiac Dysfunction Effects of the Shenfu Injection on Heart Function and Brain Natriuretic Peptide Level in CHF Patients Effect of Xinmailong Injection on Symptoms of Heart Failure, Dosage and Prognosis of Dopamine in the Middle and Advanced Stage of Middle-Aged and Elderly Patients with Dilated Cardiomyopathy. Chin Meta Analysis on Curative Effects of Yiqi Fumai Injection (Lyophilization) for Heart Failure Effect of Huangqi Injection on Hemodynamics in Patients with Clinical Study on Xinmailong Injection Combined with Milrinone in Treatment of Chronic Congestive Heart Failure The Clinical Therapeutic Effect of Shengmai Injection Combining with Levocarnitine Injection on Clinical Observation of Shenfu Injection in the Treatment of Ischemic Heart Disease with Heart Failure Effect of Shenfu Injection on NT-proBNP and Quality of Life in Patients with Chronic Heart Failure Clinical Study on the Method of Tonifying Qi and Yin in the Treatment of Chronic Heart Failure with Deficiency of Both Qi and Yin Effectiveness and Safety of Shenmai Injection in the Treatment of Heart Failure The Efficacy and Safety of Xinmailong Injection in Patients with Chronic Heart Failure: a Multicenter Randomized Double-Blind Placebo-Controlled Trial Effect of Shenfu Injection in the Treatment of Dilated Cardiomyopathy with Heart Failure and its Effect on Cardiac Function Clinical Observation of Shenfu Injection in the Treatment of 30 Cases of Dilated Cardiomyopathy with Heart Failure Effect of Shenmai Injection on LVEF and NT-proBNP of Heart Failure Patients Network Meta-Analysis of Chinese Medical Injections for Heart Failure Clinical Analysis of Shenmai Injection in the Treatment of Chronic Heart Failure Clinical Observation of Shenfu Injection in the Treatment of Chronic Congestive Heart Failure Effects of Xinmailong Injection on Vascular Endothelial Function in Elderly Patients with Chronic Heart Failure Impact of Shenfu Injection Adjunctive Therapy on Quality of Life and Survival Condition of Patients with Coronary Heart Disease with Chronic Heart Failure Treatment of 30 Cases of Chronic Heart Failure with Yiqi Fumai Injection Changes of Nitric Oxide Synthase, Adrenomedullin and Interleukin-10 in Patients with Heart Failure and Intervention Effect of Shenfu Injection. Chin Effect of Shenmai Injection Adjunctive Therapy on Echocardiographic Parameters and NT-proBNP in Patients with Chronic Heart Failure Efficacy of Yi Qi Fu Mai Injection on Heart Failure Complicated with Angina Pectoris in Patients with Coronary Heart Disease. Chin Effect of Shenmai Injection on NT-Pro-BNP and Cardiac Function in Patients with Congestive Heart Failure Shenfu injection on inflammatory cytokines and cardiac function in patients with chronic heart failure China Heart Failure Registry Study-a Multicenter, Prospective Investigation for Preliminary Analysis on Etiology, Clinical Features and Treatment in Heart Failure Patients. Chin Effect of Shenfu Injection on Cardiac Function and Ventricular Remodeling in Patients with Dilated Cardiomyopathy Associated with Heart Failure. Chin Clinical effect of Shenfu injection combined with creatine phosphate sodium in treatment of dilated cardiomyopathy-congestive heart failure The Effect of Shenmai Injection Combined with Sacubitril Valsartan on Heart Function and Hemorheology in Patients with Heart Failure Frontiers in Pharmacology | www.frontiersin.org Effect of Shengmai injection on cardiac function and coagulation function in patients with chronic heart failure Observation on therapeutic effect of Shenfu injection on chronic heart failure Effect of Xinmailong injection in the treatment of chronic heart failure and its effect on cardiac function and brain natriuretic peptide Effect of Xinmailong injection on the level of serum matrix metalloproteinase-1 in patients with congestive heart failure Prevention and treatment of COVID-19 using traditional Chinese medicine: a review Clinical observation of Yiqi Fumai injection in the treatment of chronic heart failure Clinical observation of Xinmailong injection in the treatment of heart failure in elderly patients with coronary heart disease A meta-analysis of Shenfu injection in myocardial infarction with heart failure Clinical observation of Shenfu injection on brain natriuretic peptide and exercise cardiac output in patients with chronic heart failure One hundred and seven RCTs involving 9,073 HFrEF patients were included, conducted in China from 2003 to 2021. Most RCTs focused on SF (40 RCTs, 37.38%) (Que and Guo, 2003; Song et al., 2006; Chen et al., 2009; Hu et al., 2009; Huang, 2009; Wu and Duan, 2009; Yang and Wu, 2009; Zhu, 2009; Lv, 2010; Wu and Wang, 2010; Yao and Lu, 2010; Bao and Yu, 2011; Wang et al., 2011; Wu et al., 2011; Dong, 2012; Xu et al., 2014; Yu et al., 2014; Zhang et al., 2014; Pan, 2015; Qi, 2015; Qi and Qi, 2015; Xu et al., 2015; Mao, 2016; Wang and Pan, 2016; Yao et al., 2016; Zhang and Wen, 2016; Deng and Bai, 2017; He, 2017; Yan et al., 2017; Zhang, 2017; Han, 2018; Li L. J., 2018; Liu et al., 2018; Zhang et al., 2018; Li J. P et al., 2020) , followed by XML (23 RCTs, The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.659707/ full#supplementary-material Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.